These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22875626)

  • 21. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
    Maggio A; Filosa A; Vitrano A; Aloj G; Kattamis A; Ceci A; Fucharoen S; Cianciulli P; Grady RW; Prossomariti L; Porter JB; Iacono A; Cappellini MD; Bonifazi F; Cassarà F; Harmatz P; Wood J; Gluud C
    Blood Cells Mol Dis; 2011 Oct; 47(3):166-75. PubMed ID: 21843958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges of adherence and persistence with iron chelation therapy.
    Porter JB; Evangeli M; El-Beshlawy A
    Int J Hematol; 2011 Nov; 94(5):453-60. PubMed ID: 21993873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
    Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
    Walter PB; Macklin EA; Porter J; Evans P; Kwiatkowski JL; Neufeld EJ; Coates T; Giardina PJ; Vichinsky E; Olivieri N; Alberti D; Holland J; Harmatz P;
    Haematologica; 2008 Jun; 93(6):817-25. PubMed ID: 18469351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
    Eghbali A; Shokri P; Afzal RR; Bagheri B
    Transfus Apher Sci; 2019 Aug; 58(4):429-433. PubMed ID: 31229401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R
    Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
    Forni GL; Podestà M; Musso M; Piaggio G; Musallam KM; Balocco M; Pozzi S; Rosa A; Frassoni F
    Haematologica; 2013 Apr; 98(4):555-9. PubMed ID: 23242593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
    Taher A; Al Jefri A; Elalfy MS; Al Zir K; Daar S; Rofail D; Baladi JF; Habr D; Kriemler-Krahn U; El-Beshlawy A
    Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
    Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
    Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 40. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.